North America remains a dominant region in the Non-Hodgkins Lymphoma and Chronic Lymphoma Treatment Market, owing to its well-established healthcare systems, growing cancer burden, and continuous advancements in hematologic oncology. The region benefits from strong government support for cancer research, increasing healthcare expenditure, and the rapid adoption of innovative treatment...